MindWalk Holdings Corp(HYFT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.26 | Insider Own | 9.45% | Shs Outstand | 47.0M | Perf Week | - |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 14% | Insider Trans | - | Shs Float | 42.7M | Perf Month | -9.43% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.06 | Inst Own | 9.27% | Short Float | 2.38% | Perf Quarter | -6.98% |
| Income | -0.01B | P/S | 4.82 | EPS this Y | -22.38% | Inst Trans | -0.63% | Short Ratio | 4.76 | Perf Half Y | 0.84% |
| Sales | 0.01B | P/B | 11.45 | EPS next 5Y | 4.33% | ROA | -58.96% | Short Interest | 1.01M | Perf YTD | -34.07% |
| Book/sh | 0.1 | P/C | 10.41 | EPS past 3/5Y | 35.25% 8.52% | ROE | -123.73% | 52W High | -59.87% ($2.99) | Perf Year | -25.93% |
| Cash/sh | 0.12 | P/FCF | - | Sales past 3/5Y | -10.15% -3.79% | ROIC | -174.26% | 52W Low | 21.21% ($0.99) | Perf 3Y | -34.07% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56.5% | Gross Margin | 60.79% | Volatility(W/M) | 7.22% 8.5% | Perf 5Y | -81.74% |
| Dividend TTM | - | EV/Sales | 4.57 | Sales Y/Y TTM | -26.89% | Oper. Margin | -104.08% | ATR (14) | 0.1 | Perf 10Y | 6053.85% |
| Dividend Ex-Date | - | Quick Ratio | 1.75 | EPS Q/Q | -99.36% | Profit Margin | -105.08% | RSI (14) | 41.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.84 | Sales Q/Q | 19.36% | SMA20 | -10.1% ($1.33) | Beta | 0.77 | Target Price | $4.28 |
| Payout | - | Debt/Eq | 0.5 | Earnings | 2026/9/14 | SMA50 | -10.64% ($1.34) | Rel Volume | 0.42 | Prev Close | $1.18 |
| Employees | 77 | LT Debt/Eq | 0.43 | EPS/Sales Surpr. | -71.88% -14.12% | SMA200 | -14.43% ($1.4) | Avg Volume(3M) | 0.21M | Price | $1.2 |
| IPO | 2003/11/6 | Option/Short | Yes/Yes | Trades | 218 | Volume | 88,660 | Change | 1.69% |
A global biotech company developing next-generation antibody therapeutics through its AI-powered drug discovery platform. Leveraging its proprietary LensAI™ and B Cell Llama™ technologies, the company is designing innovative new drugs targeting neurodegenerative diseases and infectious diseases.
Over the past 1 year, on the lower side
60% below its 1-year high.
Traded less than usual. That is 42% of its average volume.
HYFT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -22.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $482. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% It ranks #403 of 594 in the industry
Based on market cap of $57M.
HYFT#403 MindWalk Holdings Corp $57M PER - 
BOLD#404 Boundless Bio Inc $56M PER - 
HRTX#405 Heron Therapeutics Inc $56M PER - 
INKT#406 MiNK Therapeutics Inc $55M PER - 
CLNN#407 Clene Inc $55M PER - 
FAQ
What kind of company is HYFT?
HYFT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HYFT?
The market cap of HYFT is approximately $57M, ranking 4,790 within its sector.
What is the 52-week high and low for HYFT?
HYFT has recorded a 52-week high of $2.99 and a low of $0.99.
